Stifel raised the firm’s price target on Beam Therapeutics to $69 from $66 and keeps a Buy rating on the shares. In conjunction with the firm’s deep dive on alpha-1 antitrypsin deficiency, or AATD, the analyst is updating models to better reflect revenue contributions from three competitors’ respective AATD assets. For now, the firm assumes only BEAM-302 to be applicable in “AATD-liver disease only,” the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics price target lowered to $31 from $33 at Barclays
- Beam Therapeutics reports Q2 EPS ($1.11), consensus ($1.13)
- Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
- CRISPR Therapeutics Nears 52-Week Low. Time to Buy?
- Beam Therapeutics initiated with a Buy at H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com